Liquid Biopsy Market
Market Growth Factors:
The key factors
driving the growth of this market include increasing prevalence of
cancer, increasing preference for non-invasive procedures, initiatives
undertaken by government and global health organizations, technological
advancement to augment market revenues, rising emphasis on personalized
medicine, and availability of funding for liquid biopsy R&D.
Market Size:
According to the new market research Liquid Biopsy Market is expected to reach $2,047.9 Million by 2022 from an estimated $715.7 Million in 2017, at a CAGR of 23.4%.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350
Market Segments:
Based
on product and service, the liquid biopsy market is segmented into
assay kits, instruments, and services. Among these, the assay kits
segment is expected to be the fastest-growing segment in the product and
services market during the forecast period. Factors such as the
increasing demand for liquid biopsy tests, increasing applications of
liquid biopsies, and the need for reliable and specific assays are
expected to drive the liquid biopsy market in the coming years.
Based
on circulating biomarkers, the market is categorized into circulating
tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA
(cfDNA), extracellular vesicles (EVs) and other circulating biomarkers.
The circulating tumor DNA segment is expected to be the fastest-growing
segment in the circulating biomarkers market during the forecast period.
An increase in CTCs in a patient’s bloodstream is associated with
cancer progression, while a decrease is associated with cancer
containment or remission.
Based on application, the liquid biopsy
market is segmented into cancer and non-cancer applications (which
include reproductive health and organ transplant diagnostics). The
non-cancer application segment is expected to be the fastest-growing
segment in the market during the forecast period.
Geographic Analysis:
North
America is expected to account for the largest share of the liquid
biopsy market in 2017, followed by Europe. A number of factors such as
the easy accessibility and high adoption of advanced diagnostic
technologies (such as PCR and NGS) among healthcare professionals,
rising prevalence of cancer in the US and Canada, technological
advancements in liquid biopsy products, and growing public and private
funding to support research activities in the field of liquid biopsy are
aiding market growth in the region.
Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=13966350
Top Key Players:
The key players in the global liquid biopsy market are QIAGEN N.V. (Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories Inc. (US), Myriad Genetics, Inc. (US), Menarini Silicon Biosystems (Italy), Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Biocept, Inc. (US), Trovagene, Inc. (US), Guardant Health, Inc. (US), RainDance Technologies, Inc. (US), and MDx Health SA (US).
